ABIVAX Société Anonyme (NASDAQ:ABVX) is likely one of the finest rising know-how shares to put money into. On December 18, Guggenheim analyst Yatin Suneja raised the agency’s worth goal on ABIVAX to $175 from $150 with a Purchase score on the shares. This sentiment was posted because the agency cited its optimistic outlook for obefazimod within the 44-week upkeep readout, which is at present upcoming.
On December 15, ABIVAX reported its monetary outcomes for Q3 2025. The corporate generated $2.40 million in income, surpassing Avenue estimates by $1.06 million. Nevertheless, there was a loss per share that totaled $1.68 within the quarter. The web loss for the 9 months widened to €254.1 million, up from €136.9 million in 2024 ($297.94 million and $160.52 million respectively). The corporate’s monetary exercise displays an intensified concentrate on its lead candidate, obefazimod, a first-in-class oral miR-124 enhancer.
R&D bills rose to €133.4 million, pushed by the development of the ABTECT Section 3 program in ulcerative colitis/UC and the ENHANCE-CD Section 2b trial in Crohn’s illness. ABIVAX is getting ready for a number of main milestones in 2026. Topline outcomes from the ABTECT Upkeep Trial are anticipated within the second quarter of 2026, which is able to function the ultimate scientific basis for a deliberate NDA submission to the FDA within the second half of that yr.
ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology firm that develops therapeutics that harness the physique’s pure regulatory mechanisms to stabilize the immune response in sufferers with continual inflammatory ailments.
Whereas we acknowledge the potential of ABVX as an funding, we imagine sure AI shares provide higher upside potential and carry much less draw back danger. In case you’re on the lookout for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially revealed at Insider Monkey.
![[Vantage Point] A 12 months of reckoning: Which approach, Philippines?](https://www.rappler.com/tachyon/2025/12/vantage-point-a-year-of-reckoning-which-way-philippines-December-27-2025.jpg "[Vantage Point] A 12 months of reckoning: Which approach, Philippines?")
